Drug Profile
ATYR 1940
Alternative Names: ATYR1940; HRS(1-506); HRS(I-506); ResolarisLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator aTyr Pharma
- Class Amino acyl-tRNA synthetases; Aminoacyltransferases; Biological proteins; Peptides; Proteins
- Mechanism of Action Histidine-tRNA ligase modulators; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Facioscapulohumeral muscular dystrophy; Limb girdle muscular dystrophies; Limb girdle muscular dystrophy type 2B
- No development reported Duchenne muscular dystrophy; Interstitial lung diseases
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Duchenne muscular dystrophy in USA
- 28 Jul 2019 No recent reports of development identified for preclinical development in Interstitial lung diseases in USA (IV)
- 02 May 2018 Pharmacodynamics data from a preclinical trial presented at the American Academy of Immunology (AAI) Annual Meeting